What the FDA labels say about taking them together
Irbesartan and sparsentan
Sparsentan's FDA label of April 9, 2026 names irbesartan in its warnings and precautions section; irbesartan's label does not name sparsentan itself but warns about its class (ARBs (angiotensin II receptor blockers)). The sparsentan label: “In clinical trials, there was a greater incidence of hypotension-associated adverse events, some serious, including dizziness, in patients treated with FILSPARI compared to irbesartan.”
Check it at the source: the irbesartan FDA label on DailyMed (effective August 6, 2026, Macleods Pharmaceuticals Limited); the sparsentan FDA label on DailyMed (effective April 9, 2026, Travere Therapeutics, Inc.).
What does the irbesartan label say about sparsentan?
Irbesartan's label does not name sparsentan itself; it warns about its class (ARBs (angiotensin II receptor blockers)):
Irbesartan label, drug interactionsBlockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Irbesartan label, drug interactionsMonitor lithium levels in patients receiving irbesartan and lithium. Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including irbesartan) may result in deterioration of renal function, including possible acute renal failure.
Source: FDA drug label (Irbesartan), Macleods Pharmaceuticals Limited, effective August 6, 2026 (SPL set e8635a1c-ae06-4e23-99f7-e704f91d6f43), via openFDA; the full label on DailyMed
What does the sparsentan label say about irbesartan?
Sparsentan label, warnings and precautionsIn clinical trials, there was a greater incidence of hypotension-associated adverse events, some serious, including dizziness, in patients treated with FILSPARI compared to irbesartan [see Adverse Reactions ( 6.1 )].
Source: FDA drug label (FILSPARI), Travere Therapeutics, Inc., effective April 9, 2026 (SPL set d7354af1-f304-f4d9-e053-2995a90ab219), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Irbesartan | Sparsentan | |
|---|---|---|
| Labeled for | High blood pressure, Chronic kidney disease | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.107 per tablet 150 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once